PROCEPT BioRobotics (NASDAQ:PRCT) Stock Rating Lowered by Wall Street Zen

PROCEPT BioRobotics (NASDAQ:PRCT) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Other analysts have also issued reports about the company. Leerink Partners cut their price target on PROCEPT BioRobotics from $55.00 to $30.00 and set an “outperform” rating on the stock in a research note on Thursday. UBS Group initiated coverage on shares of PROCEPT BioRobotics in a research report on Friday, December 12th. They set a “buy” rating and a $62.00 target price on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of PROCEPT BioRobotics in a report on Thursday, January 22nd. Jefferies Financial Group downgraded shares of PROCEPT BioRobotics from a “strong-buy” rating to a “hold” rating in a research note on Thursday. Finally, Morgan Stanley cut their price target on shares of PROCEPT BioRobotics from $56.00 to $51.00 and set an “overweight” rating on the stock in a report on Tuesday, December 2nd. Eight investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, PROCEPT BioRobotics has a consensus rating of “Hold” and a consensus target price of $41.90.

PROCEPT BioRobotics Stock Performance

NASDAQ PRCT opened at $22.69 on Friday. The firm’s fifty day moving average price is $30.00 and its two-hundred day moving average price is $33.53. The stock has a market cap of $1.27 billion, a PE ratio of -13.27 and a beta of 0.99. The company has a debt-to-equity ratio of 0.14, a quick ratio of 7.20 and a current ratio of 8.44. PROCEPT BioRobotics has a fifty-two week low of $19.35 and a fifty-two week high of $66.85.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its quarterly earnings results on Wednesday, February 25th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.21). The firm had revenue of $76.38 million during the quarter, compared to the consensus estimate of $93.70 million. PROCEPT BioRobotics had a negative net margin of 31.02% and a negative return on equity of 24.82%. The firm’s revenue was up 11.9% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.35) earnings per share. On average, equities analysts expect that PROCEPT BioRobotics will post -1.75 EPS for the current fiscal year.

Hedge Funds Weigh In On PROCEPT BioRobotics

A number of hedge funds have recently bought and sold shares of PRCT. Advisory Services Network LLC boosted its position in PROCEPT BioRobotics by 1.3% during the second quarter. Advisory Services Network LLC now owns 20,109 shares of the company’s stock valued at $1,158,000 after acquiring an additional 250 shares during the last quarter. Vega Investment Solutions raised its position in shares of PROCEPT BioRobotics by 52.0% in the 2nd quarter. Vega Investment Solutions now owns 775 shares of the company’s stock worth $45,000 after acquiring an additional 265 shares in the last quarter. Frank Rimerman Advisors LLC lifted its stake in shares of PROCEPT BioRobotics by 0.3% in the 3rd quarter. Frank Rimerman Advisors LLC now owns 122,389 shares of the company’s stock valued at $4,368,000 after purchasing an additional 307 shares during the period. RiverPark Advisors LLC lifted its stake in shares of PROCEPT BioRobotics by 22.5% in the 2nd quarter. RiverPark Advisors LLC now owns 1,761 shares of the company’s stock valued at $101,000 after purchasing an additional 324 shares during the period. Finally, Osaic Holdings Inc. grew its stake in PROCEPT BioRobotics by 20.3% during the second quarter. Osaic Holdings Inc. now owns 2,001 shares of the company’s stock worth $115,000 after purchasing an additional 337 shares during the period. Institutional investors own 89.46% of the company’s stock.

PROCEPT BioRobotics News Roundup

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Company outlined a multi‑year plan and issued 2026 guidance of $390M–$410M, signaling a path to higher revenue as it pursues pricing discipline and commercial realignment; the investor day attempted to frame a roadmap to sustainable growth. PROCEPT outlines $390M–$410M revenue target for 2026
• Positive Sentiment: Certain sell‑side firms maintained constructive ratings (buy/overweight/outperform) even after trimming targets, which leaves upside scenarios if execution and revenue recovery accelerate. Analyst updates (summary)
• Neutral Sentiment: Q4 results showed revenue grew ~11.9% YoY and gross profit improved, and operating and net losses narrowed versus a year ago — a mixed quarter that demonstrates progress but also falling short of market expectations. Q4 earnings highlights
• Neutral Sentiment: Investor‑day materials and the earnings call transcript provide detail on assumptions behind guidance and the commercial reset; these are useful for modeling recovery timing but don’t eliminate execution risk. Investor Day slideshow
• Negative Sentiment: EPS and revenue missed consensus (EPS -$0.53 vs. -$0.32 estimate; revenue below forecasts), which triggered immediate downward pressure as investors re‑priced near‑term growth expectations. Q4 miss coverage
• Negative Sentiment: Several analysts cut price targets and/or downgraded the stock (examples: Jefferies to Hold; BofA to Underperform with $20 PT; Leerink, TD Cowen and Piper lowered targets), increasing short‑term downside risk and contributing to weaker sentiment. Analyst downgrades and price target changes
• Negative Sentiment: A securities‑fraud investigation by Ademi LLP into PROCEPT’s disclosures emerged, adding legal and headline risk that can prolong volatility and deter risk‑tolerant buyers. Ademi LLP investigation notice
• Negative Sentiment: Shares reached a new 52‑week low and traded at elevated volumes around these announcements, reflecting broad selling pressure and a reassessment of near‑term execution and guidance credibility. 52-week low coverage

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.